We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Advisory Council on the Misuse of Drugs’ report on the synthetic stimulant known as 4,4’-DMAR.
First published during the 2010 to 2015 Conservative and Liberal Democrat coalition government
Public Assessment Report (PAR) discussing new risk minimisation measures which are being put into place for certain over-the-counter (OTC) stimulant laxatives.
Fifteen new synthetic opioids and 5 other drugs will be banned as Class A drugs as the government continues to act to prevent drug deaths.
Methylamphetamine is a member of a broad class of psycho-stimulant compounds called amphetamines.
Accord Healthcare Ltd is recalling various batches after retesting showed out of specification results. The tabled batches are being recalled as a precautionary measure after testing showed variability of the capsule contents beyond permitted levels.
The government will place 6 new synthetic opioids under the strictest level of control.
Fifteen additional synthetic opioids are now under the strictest controls to prevent drug related deaths and ensure anyone caught supplying them faces tough penalties.
Advice on ingredients in nicotine-containing liquids in electronic cigarettes and refill containers.
Government response to the ACMD review of the evidence on the use and harms of diphenidine.
Topical steroid products are safe and highly effective treatments for the management of a wide range of inflammatory skin diseases but have important risks, especially with prolonged use at high potency. In the coming months, as a result of regulatory...
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).